What is the appropriate treatment for painful facial spasms in a patient with multiple sclerosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Painful Facial Spasms in Multiple Sclerosis

For painful facial spasms in MS patients, start with carbamazepine as first-line therapy, and if not tolerated, switch to lacosamide or other sodium channel blockers like lamotrigine, gabapentin, or oxcarbazepine. 1, 2

Understanding the Clinical Context

Facial spasms in MS typically present as two distinct entities:

  • Facial myokymia: Continuous undulating, vermicular movements that are usually self-limited, resolving within months in 27 of 28 patients regardless of treatment 3
  • Painful tonic spasms: Abrupt, brief, involuntary, and often painful muscle contractions associated with new demyelinating lesions in the corticospinal tract 2

The key distinction matters because facial myokymia often resolves spontaneously, while painful tonic spasms require active pharmacological intervention.

First-Line Pharmacological Treatment

Carbamazepine is the established first-choice medication for painful paroxysmal symptoms in MS, including both trigeminal neuralgia and painful tonic spasms 1, 4. Start at low doses and titrate upward based on response.

When Carbamazepine Fails or Is Not Tolerated

If gastrointestinal side effects, sedation, or other adverse effects limit carbamazepine use:

  • Lacosamide (50 mg twice daily) provides rapid and complete symptom resolution with better tolerability 2. This is particularly important given that MS patients are already polymedicated and vulnerable to sedative and motor adverse effects 4
  • Alternative anticonvulsants include lamotrigine, gabapentin, or oxcarbazepine 1

Second-Line and Adjunctive Options

For chronic "burning" dysesthesias or when first-line agents are insufficient:

  • Tricyclic antidepressants as per neuropathic pain guidelines 5, 1
  • Gabapentin (up to 1800 mg/day) 6, 1
  • Consider escalation to opioids only in refractory cases, though central neuropathic pain in MS may be relatively more refractory to treatment than peripheral neuropathic pain 5

Botulinum Toxin for Persistent Cases

For continuous facial myokymia persisting beyond 1 month, botulinum toxin A injections are effective and safe 7. Two cases demonstrated complete resolution after BTX-A injection when myokymia persisted troublesomely 7. This is particularly relevant since facial myokymia in MS is associated with an ipsilateral pontine lesion in only a minority of patients 3.

Critical Pitfalls to Avoid

  1. Don't assume all facial spasms are the same: Facial myokymia is self-limited; painful tonic spasms require treatment 3
  2. Don't persist with carbamazepine if poorly tolerated: MS patients are already burdened with multiple medications, and sedative/motor side effects significantly impact quality of life 4. Switch to lacosamide early 2
  3. Don't overlook imaging: New facial spasms may indicate a new demyelinating lesion requiring disease-modifying therapy adjustment 3, 2
  4. Medication burden matters: Even modest analgesic improvement with reduced medication load represents meaningful gains in MS patients 4

Treatment Algorithm

  1. Confirm the diagnosis: Distinguish facial myokymia (usually self-limited) from painful tonic spasms (requires treatment)
  2. Obtain MRI: Look for new pontine or cerebral peduncle lesions 3, 2
  3. Start carbamazepine as first-line
  4. If not tolerated within days: Switch to lacosamide 50 mg twice daily 2
  5. If persistent beyond 1 month (especially myokymia): Consider botulinum toxin A injections 7
  6. If refractory: Add gabapentin or tricyclic antidepressants for neuropathic pain component 5, 1

The evidence strongly supports sodium channel blockers as the foundation of treatment, with lacosamide emerging as a highly effective and well-tolerated alternative when carbamazepine cannot be used 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.